Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.


A promising drug target currently under investigation to improve cognitive deficits in neuropsychiatric and neurological disorders is the neuronal nicotinic alpha7 acetylcholine receptor (α7nAChR). Improving cognitive impairments in diseases such as Alzheimer's (AD) and schizophrenia remains a large unmet medical need, and the α7nAChR has many properties… (More)
DOI: 10.1016/j.bcp.2011.06.034


2 Figures and Tables

Slides referencing similar topics